Phosphatase isoenzymes as bone metastasis markers in prostatic carcinoma.
Bone alkaline phosphatase (b-ALP) and tartrate resistant acid phosphatase (tr-ACP) are markers of the activity of osteoblasts and osteoclasts, respectively. We have already shown that the serum activity of these isoenzymes was elevated in breast cancer patients with bone metastasis (BM); we show here that the serum activity of b-ALP and tr-ACP were also elevated in prostate cancer patients with BM. Specificity and sensitivity of b-ALP for BM were 0.90 and 0.75, respectively; and for tr-ACP, 0.60 and 0.60, respectively. The accuracy of b-ALP as a BM marker was higher than the accuracy of usual markers of prostatic carcinoma (tartrate labile ACP [tl-ACP], prostatic acid phosphatase [PAP] and prostate specific antigen [PSA]). The highest value predictive of a positive bone scan was obtained with b-ALP (0.88); this increased to 0.97 when b-ALP was coupled with PAP.
Desoize
B
B
Laboratoire de Biochimie GIBSA, Institut Jean Godinot, Reims, France.
Amico
S
S
Larbre
H
H
Coninx
P
P
Jardillier
J C
JC
D000135:Acid Phosphatase / Q000097:blood; D000469:Alkaline Phosphatase / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D001859:Bone Neoplasms / Q000201:enzymology / Q000556:secondary*; D006801:Humans; D007527:Isoenzymes / Q000097:blood*; D008297:Male; D011471:Prostatic Neoplasms / Q000201:enzymology* / Q000473:pathology
D014408:Biomarkers, Tumor; D007527:Isoenzymes; D000469:Alkaline Phosphatase; D000135:Acid Phosphatase